Cargando…

Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia

BACKGROUND AND OBJECTIVES: Cells of innate immunity normally recover in the first weeks to months after allogenenic hematopoietic stem cell transplantation (allo-HSCT). Their relevance in terms of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect is largely unknown. The predict...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tae Woo, Park, Sung-Soo, Lim, Ji-Young, Min, Gi June, Park, Silvia, Jeon, Young-Woo, Yahng, Seung-Ah, Shin, Seung-Hwan, Lee, Sung-Eun, Yoon, Jae-Ho, Cho, Byung-Sik, Eom, Ki-Seong, Lee, Seok, Kim, Hee-Je, Min, Chang-Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Stem Cell Research 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457701/ https://www.ncbi.nlm.nih.gov/pubmed/30595008 http://dx.doi.org/10.15283/ijsc18094

Ejemplares similares

Second Primary Glioblastoma Multiforme Following Autologous Hematopoietic Stem Cell Transplantation in a Patient with Acute Myelogenous Leukemia
por: Kim, Eun-Oh, et al.
Publicado: (2011)

Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)

Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Lee, Tae Hyang, et al.
Publicado: (2013)

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma
por: Jeon, Young-Woo, et al.
Publicado: (2019)

SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation
por: Shin, Seung-Hwan, et al.
Publicado: (2015)

Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission
por: Yoon, Jae-Ho, et al.
Publicado: (2016)

HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation
por: Shin, Seung-Hwan, et al.
Publicado: (2013)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
por: Yoon, Jae‐Ho, et al.
Publicado: (2019)

Acute colonic pseudo-obstruction following allogeneic stem cell transplantation successfully treated by neostigmine
por: Yahng, Seung-Ah, et al.
Publicado: (2013)

Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?
por: Min, Gi-June, et al.
Publicado: (2022)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Incidence, Management, and Prognosis of Graft Failure and Autologous Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
por: Park, Jun-Hong, et al.
Publicado: (2021)

The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma
por: Min, Chang-Ki, et al.
Publicado: (2013)

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1
por: Cho, Byung-Sik, et al.
Publicado: (2021)

The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population
por: Lee, Hyo-Jin, et al.
Publicado: (2017)

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts
por: Yahng, Seung-Ah, et al.
Publicado: (2016)

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia
por: Cho, Byung‐Sik, et al.
Publicado: (2019)

Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

A Case Report of the Second de Novo Acute Myeloid Leukemia (AML) Following Allogeneic Stem Cell Transplantation in a Patient with the First AML
por: Cho, Byung-Sik, et al.
Publicado: (2010)

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
por: Shin, Seung-Hwan, et al.
Publicado: (2017)

Toxoplasma Encephalitis in an Allogeneic Hematopoietic Stem Cell Transplant Recipient in Korea
por: Park, Soo-Kyung, et al.
Publicado: (2012)

Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome
por: Park, Silvia, et al.
Publicado: (2021)

Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study
por: Park, Sung-Soo, et al.
Publicado: (2023)

Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study
por: Yi, Hyeon Gyu, et al.
Publicado: (2016)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning–Based Model Development and Validation
por: Choi, Eun-Ji, et al.
Publicado: (2022)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study
por: Park, Sung-Soo, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
por: Lee, Je-Hwan, et al.
Publicado: (2010)

Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2019)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_neenniermfl3r5apnmdambeeef